Patent 10004725 was granted and assigned to Global Blood Therapeutics on June, 2018 by the United States Patent and Trademark Office.
This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.